Intractable and highly active relapsing multiple sclerosis - role of alemtuzumab.

Neuropsychiatr Dis Treat · 2015 · PMC4581781 · PMID 26425095

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Interestingly, there was a 56% reduction in relapse rate in the alemtuzumab-treated group compared to the INF-β1a-treated group from years 3 to 5 of the study, which did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.